References to Primary Literature
- CLAESON G: Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other pro-teases in the blood coagulation system- Blood Coagul. Fibrin. (1994) 5:411.
- VERSTRAETE M, ZOLDHELYI P: Novel antithrombotic drugs in development. Drugs (1995) 49:856.
- VERSTRAETE M: New developments in antiplatelet and antithrombotic therapy. Fur. Heart f. (1995) 16(Suppl. L):16.
- VLASUK GP: Structural and functional characterizationof tick anticoagulant peptide (TAP): a potent and selec-tive inhibitor of blood coagulation factor Xa. Thromb. Haemostas. (1993) 70:212.
- DUNW1DDIE CT, WAXMAN L, VLASUK GP et al.: Purifica-tion and characterization of inhibitors of blood coagu-lation factor Xa from hematophageous organisms. Methods Enzymol. (1993) 223:291.
- CHOAY J, PET1TOU M, LORMEAU JC et al.: Structure-activ-ity relationships in heparin: a synthetic pentastiecha-ride with high affinity for antithrombotin M and eliciting high anti-factor Xa activity. Biochem. Biophys. Rev. Commun. (1983) 116:492.
- VAN BOECKEL CAA, PETITOU M: The unique antithrom-bin 111 domain of heparin leads to new synthetic an-tithrombotics. Angew. Chem. Int. Ed. Engl. (1993) 12:1671.
- AL-OBEIDI FAD, WILDGOOSE P, STRINGER SK et al.: Discovery and optimization of a specific, orally avail-able, active site inhibitor of factor Xa discovered using synthetic combinatorial chemistry. J. Invest. Med. (1995) 43\(Suppl. 2):232A.
- NAGAHARA T, YOKOYAMA Y, INAMURA K et al.: Dibasic(amidinoaryfipropartok acid derivatives as novel blood coagulation factor Xa inhibitors. J. Med. Chem, (1994) 37:1200.
- NAGAHARA T, KATAKURA SI, YOKOYAMA Y et al.: Design,synthesis and biological activities of orally active coagu-lation factor /Ca inhibitors. Eur. J. Med. Chem, (1995) 30:139s.
- HARA T, YOKOYAMA A, MORISHIMA Y et al.: Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb. Res. (1995) 80:99.
- HARA T, YOKOYAMA A, ISHIHARA H et al.: DX-9065a, anew synthetic, potent anticoagulant and selective in-hibitor for factor Xa. Thromb. Haemostas. (1994) 71:314.
References to Patent Literature
- MERCK & CO., INC., EP-419099 (1991).
- SELECTIDE CORPORATION, W09529189 (1995).
- DAIICHI PHARMACEUTICAL CO. LTD., EP-540051 (1993).